IFOSFAMIDE, METHOTREXATE, AND VINCRISTINE (IMV) COMBINATION CHEMOTHERAPY AS SECONDARY-TREATMENT FOR PATIENTS WITH MALIGNANT-LYMPHOMA
- 1 January 1980
- journal article
- research article
- Vol. 64 (8-9) , 933-937
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group studyCancer, 1979
- Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy-Resistant Non-Hodgkin LymphomaAmerican Journal of Hematology, 1978
- Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapyThe American Journal of Medicine, 1977
- COMBINATION CHEMOTHERAPY (CHOP-BLEO) IN ADVANCED (NON-HODGKIN) MALIGNANT-LYMPHOMA1977
- COMBINATION CHEMOTHERAPY OF ADVANCED NON-HODGKIN LYMPHOMA WITH BLEOMYCIN, ADRIAMYCIN, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (BACOP)1977
- Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) Combination Chemotherapy in the Treatment of Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1976
- REDUCTION OF IFOSFAMIDE TOXICITY USING DOSE FRACTIONATION1976